Objective To investigate the effects of early introduction of biologic disease‐modifying
antirheumatic drugs (bDMARDs) on the disease course in untreated polyarticular juvenile …

Objectives A 24-hour urine protein (24hUP) is a key measurement in the management of
lupus nephritis (LN); however, trajectories of 24hUP in LN is poorly defined. Methods Two …

Objectives Disease activity status described at fixed time points does not accurately reflect
disease course in chronic and relapsing diseases such as rheumatoid arthritis (RA). We …

Abstract Background Leveraging Alzheimer's disease (AD) imaging biomarkers and
longitudinal cognitive data may allow us to establish evidence of cognitive resilience (CR) to …

Latent class trajectory models (LCTMs) are often used to identify subgroups of patients that
are clinically meaningful in terms of longitudinal exposure and outcome, eg drug response …

Novel machine learning methods open the door to advances in rheumatology through
application to complex, high-dimensional data, otherwise difficult to analyse. Results from …

Lack of sufficient head-to-head trials comparing biologic disease-modifying antirheumatic
drugs (bDMARDs) in rheumatoid arthritis (RA), makes the choice of the first bDMARD a …

Background Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune
condition for which there are limited licensed therapies. Clinical trial design is challenging in …

To characterize disease activity trajectories and compare long-term drug retention between
rheumatoid (RA) and spondylarthritis (SpA) patients initiating tumor necrosis factor inhibitor …

Clinical outcomes are measurable changes in health, function or quality of life that result
from patients' care. The capability of predicting changes related to specific care actions …